Chaime Orlev News Today

Largest Commercial Agreement in Kamada’s History Becomes Effective in January 2024 and Includes $180 Million of Revenues to Kamada Over the First Four Years of the Eight Year TermFinancial Terms...

Kamada Provides Corporate Update on its Israel Operations Rehovot, Israel, and Hoboken, NJ - October 10, 2023 -- Kamada Ltd. , a commercial stage global biopharmaceutical...

The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023 ...

Operator: Greetings and welcome to the Kamada Ltd. First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-YearFirst Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-YearSolid First Quarter Results and Expected... | May 24, 2023

Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-YearFirst Quarter 2023 EBITDA of $3.8 Million, Increase of 16%...

REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 -- Kamada Ltd. , a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions... | June 11, 2023

Operator: Greetings. Welcome to the Kamada Ltd. Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Kamada Files Annual Report for the Year Ended December 31, 2022 REHOVOT, Israel, and Hoboken, NJ - March 15, 2023 -- Kamada Ltd. , a commercial stage global biopharmaceutical... | March 15, 2023

REHOVOT, Israel and HOBOKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products